Neuropathy Tx protocol

doi:10.15406/hpmij.2024.07.00252

eISSN: 2576-4497

Hospice & Palliative Medicine International Journal

Opinion Volume 7 Issue 3

Neuropathy Tx protocol

Robert H Odell

Verify Captcha

Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.

Anesthesiologist, Neuropathy & Pain Center Las Vegas, US

Correspondence: Robert H Odell, Anesthesiologist, Neuropathy & Pain Center Las Vegas, US, Tel + 702 2577246

Received: June 14, 2024 | Published: September 26, 2024

Citation: Odell RH. Neuropathy Tx protocol. Hos Pal Med Int Jnl. 2024;7(3):112-113. DOI: 10.15406/hpmij.2024.07.00252

Download PDF

Opinion

The purpose of this communication is described the neuropathy treatment protocol in detail. The Sanexas device has been shown to be highly effective in the treatment of peripheral neuropathy and other forms of Mononeuropathies.

Mechanisms of action

Mechanisms of action are beyond the scope of this paper. Briefly, the advanced electronic cell treatment therapy that is provided by the Sanexas device his able to reprogram the neurons to either heel or when they regenerate, regenerating such a way as to minimize or eliminate the pathophysiology that is causing the neuropathy. These critical interventions include the serial blocking of pain fiber signals using both depolarization and hyperpolarization techniques. Increasing cyclic AMP to promote nerve cell regeneration, immune system support and other well documented physiologic changes which optimize and accelerate the body's own repair and regenerative processes. Some of the specific mechanisms include muscle relaxation, increasing circulation, neuromuscular reeducation, and maintaining more increasing range of motion.^1–5

This electronic cell signaling works by physiologic stimulation and multi facilitation which include physiological effects induced without action potentials, including by a chemical effect. Peripheral neuropathy defined: For the purposes of this paper, peripheral neuropathy is defined as distal symmetric polyneuropathy. All principles however can be applied to mono neuropathies with the same results. In most cases, the diagnosis is straight forward since patients present with distal, symmetric lower extremity symptoms of numbness and possible pain and dysesthesias. We further utilize an A-delta nerve conduction sensory (NCS) test to document the peripheral neuropathy.^1,6–9When a patient has neuropathy due to diabetes, chemotherapy, or idiopathic, located in the feet, the initial work up includes an initial evaluation along with objective testing with Neural scan neuro diagnostic testing, Epidermal nerve fiber density testing, and a standard neuropathy questionnaire. The patient will undergo three treatments per week with EST for a total of three treatments per week for 3-6 weeks. Vasopneumatic electrodes are utilized for the EST.^10–13 These electrodes utilize suction technology to significantly increase circulation at the electrode placement site and decrease skin resistance which widens the effective electric fie d over the affected area. The montage (placement of electrodes) will be determined by the pain pattern, but in the lower extremities is usually on the posterolateral calves and tops and bottoms of the feet. The treatment plan for the patient may also include as series of integrated ankle blocks performed twice a week utilizing Marcaine local anesthetic along with the electronic signal treatment (EST),^14–18 often beginning after 3-4 weeks of Sanexas only depending on the patient progress. A majority of patients will not need the blocks. This Sanexas protocol will continue for 3-6 weeks, with a complete re-evaluation at that time of neuropathic symptoms and the response to treatment. If needed, the injections are conducted with relatively small volumes of dilute solutions of the local anesthetic Marcaine targeted to the symptomatic peripheral nerves as determinec by the patient's reporting and neurodiagnostic testing.¹⁹ The multiple injection regimen has been found to he effective in conjunction with EST in reducing or eliminating neuropathic pain without the need for systemic medications or steroids in more refractory patients.^20–26The patient will be given blocks as needed over a two-to-four-week time period, depending on the patient's progress and disease severity.²⁷ Re-evaluations will continue after every four subsequent ankle blocks and will be discontinued after the patient's progress (decrease in pain and numbness, improved gait, etc.) has plateaued. At this time repeat Neuralscan and ENFD testing can be performed to accomplish an objective measure of the patient's response.²⁸

Protocol

Protocol consists of treatment of the affected region, usually the lower extremities three times a week for 25-minute treatment periods. Protocols are divided between diabetic and nondiabetic neuropathy. After the proper protocol has been chosen, the patient is begun on the first week. The protocol spread sheets w II guide the therapist in what programs to use on each visit.^29,30 These change weekly. As the patient moves through the various weeks, the programs are changed accordingly. The patient is re-examined by a practitioner after approximately ten treatments. The montage (electrode placerrent) is usually over the posterolateral calves and tops and bottoms of the feet (as indicated above). All treatment alterations are at the discretion of the practitioner.

Conclusion

The treatment is successful more than 80% of the time. Risks are virtually zero, limited to occasional burns used by poorly trained technicians.

Acknowledgments

None.

Conflicts of interest

The author declared that there are no conflicts of interest.

References

Odell RH, Sorgnard RE, May HU. Electroanalgesic medical device. Practical Pain Management. 2006;6(3):52–68.
Odell RH, Sorgnard RE. Anti-inflammatory effects of electronic signal treatment. Pain Physician. 2008;11(6):891–907.
Odell RH, Woessner JW. Electric nerve blocks, poster presentation to international spine intervention society (now SIS) Annual Conference; Las Vegas. 2008.
Cernak C, Odell R, Marriott E, et al. Combination electrochemical therapy (CET) to treat patients with diabetic neuropathy; Poster presentation, American Society of Regional Anesthesia (ASRA) 35th Annual Meeting & Workshops, Toronto, CA. 2010.
Odell RH, Sorgnard, RE. New technique combines electrical currents and local anesthetic for pain management. Practical Pain Management. 2011;11(5):52–68.
Cernak C, Marriot E, Martini M, et al. Electric current and local anesthetic combination successfully treats pain associated with diabetic neuropathy. Practical Pain Management. 2012.
Odell R, Carney P, Sorgnard R. The combination electrochemical block in the treatment of peripheral neuropathy: Preliminary Results; Poster presentation, World Institute of Pain (WIP) 6th World Congress, Miami, FL, 2012.
Odell RH. American Association of Sensory Electro-diagnostic Medicine 10th Annual (AASEM) Scientific Conference, Faculty, Newport Beach, CA, 2012.
Milne RD, Sorgnard RE. Quantum theory underpins electromagnetic therapies for pain management. Practical Pain Management. 2013;13(1):1–7.
Odell RH. The use of electro-diagnostic data to direct care & provide objective proof of benefit. Treating neuropathy and spine pain with the combined electrochemical block. AASEM 11th Annual Scientific Conference, Faculty, Costa Mesa, 2014.
Carney PM. Quantum theory treats neuropathy better than pharmacology. Award winning poster presentation at the American academy of pain management annual meeting. 2014.
Carney PM. Peripheral neuropathy treatment taps into quantum theory. Medscape; AAPM 25th Annual Clinical Meeting, 2014.
Odell R, Sorgnard R. Combination electrochemical treatment (CET) for peripheral neuropathy. AAPM, Phoenix, AZ, 2014.
Cernak C, Odell RH, Carney PM. Can combined electrochemical treatment have an impact for diabetic peripheral neuropathy? 2014.
Odell R, Chaya Z. Clinical outcomes utilizing the combined electrochemical treatment for peripheral neuropathy: a retrospective study from a Western Clinic. ASRA, San Francisco, CA; 2014.
Carney PM. Effectively Treating CIPN. ASCO Annual Meeting Abstract; 2015.
Odell RH, Sorgnard RE, Milne R, Cary RM. Mitigating phantom-limb pain with electric cell signaling – a case report. Prac Pain Mgment. 2015.
Odell RH, Sorgnard RE. Electronic signal treatment can restore peroneal nerve function in patients with foot drop poster presentation ASRA; Las Vegas.2015.
Carney PM, Odell RH. Regenerating nerves destroyed by peripheral neuropathy. NeuPSIG Conference, Nice, FR; 2015.
Cernak C, Larsen EM, Odell RH. Mitigating some guesswork in treating neuropathic pain. 2015;28(6):16–19.
Carney PM. Novel treatment can regenerate nerves damaged by peripheral neuropathy. Pain Medicine News. 2016.
Carney PM. Helping patients with pain from peripheral neuropathy (PPN) without harming them. New York; World Institute of Pain World Congress, 2016.
Odell RH Carney P. Reclaiming the art of medicine: prospective & case studies in the treatment of neuropathic and myofascial pain. New York; World Institute of Pain World Congress, 2016.
Cernak C Odell RH. A paradigm shift: combined electrochemical treatment for neuropathic and other refractory pain syndromes. Pain Week Journal.
Odell RH, Chaya Z. Clinical Outcomes utilizing the combined electrochemical treatment for peripheral neuropathy: a retrospective study from a western clinic. Gavin J of Anes: 2016.
Carney PM, Odell RH. Successful opioid reduction when treating pain by using electric cell signaling, Midwest pain society conference, Chicago, 2016.
Carney PM, Sorgnard RE, Odell RH. Electric cell signaling of nerves reduces the need for opiates. AAPM; Annual Meeting Abstracts Poster 100, Pain Medicine 2017.
Odell RH, Carney. Regenerating nerves damaged or destroyed by neuropathy. AAPM; Annual Meeting Abstracts Poster L106, Pain Medicine. 2017.
Odell R, Sorgnard R. Combined electrochemical treatment (CET) for refractory myofascial pain - a case report. Brain Nerv Sys Curr Res. 2017;1:1–7.
Sorgnard R, Milne R, Odell RH. Utilization of electronic cell signaling to effect recovery from peroneal neuropathy in patients with complete foot drop. J Spine Neurosurg. 2017;6(3).